Contact
searchSearch
HMP Global

HEOR

Featured Article

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Jolynn Tumolo
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
Headshot of Merle Diamond, MD, Diamond Headache Clinic, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Migraine's Impact on Productivity, Quality of Life
05/19/2022
Edan Stanley; Maria Asimopoulos
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH,...
05/19/2022
First Report Managed Care
Headshot of Gary Owens, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
How Payers Can Use Clinical, Value Comparison Data for Atopic Dermatitis Therapy
09/24/2021
Edan Stanley
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of...
09/24/2021
First Report Managed Care
News
Screening for Spinal Muscular Atrophy Enhances Nusinersen Cost-Effectiveness
01/22/2021
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for...
01/22/2021
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
Videos
Discussing Treatment Paradigm Shifts, Successful Therapy Options for Atopic Dermatitis
11/13/2020
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate...
11/13/2020
First Report Managed Care
Literature Review
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
10/23/2020
Julie Gould
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen...
10/23/2020
First Report Managed Care
Podcasts
Weighing Benefits and Challenges to Effectively Treat Atopic Dermatitis
09/16/2020
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake...
09/16/2020
First Report Managed Care
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
News
Examining the Cost-Effectiveness of DLBCL Treatment
08/27/2020
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed...
08/27/2020
First Report Managed Care
Podcasts
Discussing Effectiveness, Persistence Rates for Atopic Dermatitis Therapy
08/13/2020
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD,...
08/13/2020
First Report Managed Care

Newsfeed

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Jolynn Tumolo
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
Conference Insider
Latanoprostene Bunod Proves Cost-Effective for Primary Open-Angle Glaucoma
11/20/2019
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin...
11/20/2019
First Report Managed Care
News
Longer Hemodialysis Treatment Time Linked to Improved Survival in US Cohort
07/10/2026
Grace Taylor, MS, MA
A large US study found that extending in-center hemodialysis treatment time to approximately 4 hours was associated with lower mortality, fewer hospitalizations, and shorter hospital stays, highlighting a potentially modifiable factor in...
A large US study found that extending in-center hemodialysis treatment time to approximately 4 hours was associated with lower mortality, fewer hospitalizations, and shorter hospital stays, highlighting a potentially modifiable factor in...
A large US study found that...
07/10/2026
First Report Managed Care
Behind the Bill
CMS Proposes Broad Changes to Medicare Home Health Payment and Oversight
07/10/2026
Hannah Musick
The Centers for Medicare & Medicaid Services’ (CMS) proposed 2027 Home Health Prospective Payment System rule goes beyond a routine payment update, introducing changes to reimbursement, quality reporting, provider oversight, and program...
The Centers for Medicare & Medicaid Services’ (CMS) proposed 2027 Home Health Prospective Payment System rule goes beyond a routine payment update, introducing changes to reimbursement, quality reporting, provider oversight, and program...
The Centers for Medicare &...
07/10/2026
First Report Managed Care
News
TKI Discontinuation Supports Long-Term Treatment-Free Remission in Chronic-Phase CML
07/08/2026
Grace Taylor, MS, MA
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies...
07/08/2026
First Report Managed Care
News
Tirzepatide Demonstrates Improved Clinical Benefit and Lower Costs than Semaglutide in Adults With Obesity
07/08/2026
Rebecca Amrick
A simulation model demonstrated that tirzepatide had better clinical outcomes and less medical costs than semaglutide for patients with obesity or overweight, supporting prior research that highlighted tirzepatide as a viable treatment...
A simulation model demonstrated that tirzepatide had better clinical outcomes and less medical costs than semaglutide for patients with obesity or overweight, supporting prior research that highlighted tirzepatide as a viable treatment...
A simulation model demonstrated...
07/08/2026
First Report Managed Care
News
Electronic Interventions Could Reduce Reliance on Benzodiazepines
07/06/2026
Rebecca Amrick
Electronic interventions could allow patients taking benzodiazepines to actively manage their prescriptions and reduce drug reliance, which would improve self-management of care without excessive cost burdens.
Electronic interventions could allow patients taking benzodiazepines to actively manage their prescriptions and reduce drug reliance, which would improve self-management of care without excessive cost burdens.
Electronic interventions could...
07/06/2026
First Report Managed Care
News
Real-World Study Supports Omalizumab for Food Allergy Management
07/02/2026
Hannah Musick
Real-world data suggest that omalizumab enabled most patients with food allergy to successfully tolerate oral food challenges and introduce previously allergenic foods into their diets, with generally manageable allergic reactions during...
Real-world data suggest that omalizumab enabled most patients with food allergy to successfully tolerate oral food challenges and introduce previously allergenic foods into their diets, with generally manageable allergic reactions during...
Real-world data suggest that...
07/02/2026
First Report Managed Care
Behind the Bill
House Advances Bipartisan Legislation to Ease Quality Reporting Burden for Medicare ACOs
07/02/2026
Grace Taylor, MS, MA
The US House of Representatives (House) unanimously approved H.R. 5347, bipartisan legislation that would provide greater flexibility for Medicare Accountable Care Organizations (ACOs) transitioning to digital quality reporting.
The US House of Representatives (House) unanimously approved H.R. 5347, bipartisan legislation that would provide greater flexibility for Medicare Accountable Care Organizations (ACOs) transitioning to digital quality reporting.
The US House of Representatives...
07/02/2026
First Report Managed Care
Behind the Bill
Medicare Cost Cap Act Would Establish Out-of-Pocket Maximum in Traditional Medicare
06/26/2026
Grace Taylor, MS, MA
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would...
06/26/2026
First Report Managed Care
News
Omalizumab Associated With Reduced HCRU and Disease-Related Costs for Food Allergies and Asthma
06/25/2026
Rebecca Amrick
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in...
06/25/2026
First Report Managed Care
News
Social Determinants of Health Negatively Impact Mortality Among Patients With ESKD
06/24/2026
Rebecca Amrick
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage...
06/24/2026
First Report Managed Care

Literature Review

Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Kara Rosania, MS
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Danielle Sposato
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
Danielle Sposato
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
Edan Stanley
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
Edan Stanley
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
Edan Stanley
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
Jeff Craven
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
Edan Stanley
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
Edan Stanley
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Edan Stanley
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

Literature Review

Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Kara Rosania, MS
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Danielle Sposato
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
Danielle Sposato
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
Edan Stanley
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Maria Asimopoulos
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
Edan Stanley
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
Edan Stanley
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
Jeff Craven
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
Edan Stanley
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
Edan Stanley
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Edan Stanley
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

First Report

First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
Vibegron Proves Effective as Oral Therapy for Patients With Overactive Bladder
04/12/2021
Edan Stanley
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with high mortality rates, its effects on quality of life and overall burden can be stressful to patients and diagnosis/treatment is often delayed due to patients’ lack of understanding of available treatments.
While OAB is not associated with...
04/12/2021
First Report Managed Care
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
First Report
Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
08/31/2020
Edan Stanley
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was...
08/31/2020
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use